Janney Montgomery Scott
CRNX icon

Janney Montgomery Scott’s Crinetics Pharmaceuticals CRNX Stock Holding History

Janney Montgomery Scott’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,975
Closed -$254K – 2693
2024
Q4 		$254K Buy
4,975
+600
+14% +$33.6K ﹤0.01% 2412
2024
Q3 		$224K Buy
+4,375
New +$226K ﹤0.01% 2464

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janney Montgomery Scott's CRNX Position: Q1 2025 in Review

Janney Montgomery Scott sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2025, closing a stake of 4,975 shares — an estimated $254K sold.

Janney Montgomery Scott first reported a position in CRNX in Q3 2024 and held it in 2 quarters. The position peaked at $254K in Q4 2024. 227 funds tracked by Wall St. Rank hold CRNX as of Q1 2025.

  • Janney Montgomery Scott reported no remaining Crinetics Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Janney Montgomery Scott sold 4,975 Crinetics Pharmaceuticals shares in Q1 2025, an estimated $254K.
  • Janney Montgomery Scott first reported a position in Crinetics Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Janney Montgomery Scott's Crinetics Pharmaceuticals position peaked at $254K in Q4 2024.
  • 227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2025.

Based on Janney Montgomery Scott's 13F filing for Q1 2025, filed 17 Apr 2025.